For immediate release
Chicago, IL – July 14, 2022 – Zacks.com announces the list of stocks featured in the analyst blog. Every day, Zacks Equity Research analysts discuss the latest news and events impacting stocks and financial markets. Stocks recently featured in the blog include: Pfizer Inc. PFE, Raytheon Technologies Corp. RTX, Diageo plc DEO, Infosys Ltd. INFY and Canadian Pacific Railway Ltd. CP.
Here are highlights from Wednesday’s analyst blog:
Top analyst reports for Pfizer, Raytheon and Diageo
Zacks Research Daily features top research results from our team of analysts. Today’s Research Daily features new research reports on 16 major stocks, including Pfizer Inc., Raytheon Technologies Corp. and Diageo plc. These research reports have been handpicked from the approximately 70 reports published today by our team of analysts.
You can see all research reports from today here >>>
Pfizer shares have outperformed industry Zacks Large Cap Pharmaceuticals over the past year (+34.7% vs. +17.6%). The company has a diverse portfolio of innovative drugs and vaccines, including Ibrance and Prevnar. The Zacks analyst believes that no company is as strongly positioned in the COVID vaccine/treatment market as Pfizer at present.
Its COVID-19 vaccine has become a key revenue contributor. The vaccine combined with Pfizer’s promising oral antiviral pill for COVID-19, Paxlovid, is expected to generate combined sales of $54 billion in 2022. Pfizer has a sustainable pipeline with several late-stage programs that can stimulate growth.
However, currency headwinds and pricing pressure are the main revenue headwinds. Concerns remain about long-term growth drivers beyond its COVID-related products due to competitive pressure.
(You can read the full research report on Pfizer here >>>)
Raytheon Technologies shares have outperformed industry Zacks Aerospace – Defense Equipment over the past year (+13.4% vs -0.8%). The company continues to receive numerous orders from the Pentagon for its combat-proven defense products. It expects the growth of domestic and international programs to boost its defense activities.
Raytheon realized $90 million in additional merger synergies in the first quarter. Looking ahead, the company aims to realize $335 million in incremental cost synergies in 2022. The stock is in a strong solvency position.
However, economic sanctions imposed by governments in response to Russia’s invasion of Ukraine could hurt Raytheon. A comparative analysis of its 12-month price-to-book ratio paints a relatively bleak picture. The decline in purchase orders, seen lately, with order delays from OEM customers posing a risk to inventory.
(You can read the full research report on Raytheon Technologies here >>>)
Diageo shares are down -9.6% over the past year compared to the -10.0% industry decline of Zacks Beverages – Alcohol. The company faces continued inflationary pressures and currency headwinds are a concern. Nonetheless, margin growth was driven by supply productivity savings and price increases, which more than offset rising costs.
It provided a good outlook for FY2022, with organic sales momentum likely to continue in the second half of FY2022. However, continued recovery in the on-trade channel, strong consumer demand in contributing to business performance in the first half of fiscal 2022.
The company reported growth in sales, operating margin and earnings in the first half of fiscal 2021, driven by organic sales growth across all regions. A strong recovery in gross margin and operating cost leverage as well as higher marketing investments contributed to the organic growth in operating margin.
(You can read the full Diageo research report here >>>)
Other noteworthy reports we’re featuring today include Infosys Ltd. and Canadian Pacific Railway Ltd.
Why haven’t you watched Zacks best action?
Our top 5 performing strategies swept away the S&P’s impressive +28.8% gain in 2021. Surprisingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today, you can access their live selections at no cost or obligation.
See Free Stocks >>
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is not indicative of future results. The potential for loss is inherent in any investment. This document is provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold any security. No recommendation or advice is given as to whether any investment is suitable for any particular investor. It should not be assumed that investments in the securities, companies, sectors or markets identified and described have been or will be profitable. All information is current as of the date hereof and is subject to change without notice. The views or opinions expressed may not reflect those of the company as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management of securities. These returns come from hypothetical portfolios composed of stocks with Zacks Rank = 1 that have been rebalanced monthly without transaction fees. These are not the returns of actual stock portfolios. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for more information on the performance figures displayed in this press release.
Zacks names ‘only one best choice for doubling up’
From thousands of stocks, 5 Zacks experts have each picked their favorite to skyrocket by +100% or more in the coming months. Of these 5, Research Director Sheraz Mian selects one to have the most explosive advantage of all.
It’s a little-known chemical company that’s up 65% year-on-year, but still very cheap. With relentless demand, rising earnings estimates for 2022 and $1.5 billion for stock buybacks, retail investors could jump in at any moment.
This company could rival or surpass other recent Zacks stocks which are expected to double, such as Boston Beer Company which jumped +143.0% in just over 9 months and NVIDIA which jumped +175.9% in one. year.
Free: See our best stock and our 4 finalists >>
Click to get this free report
Pfizer Inc. (PFE): Free Inventory Analysis Report
Infosys Limited (INFY): Free Stock Analysis Report
Diageo plc (DEO): Free Stock Analysis Report
Canadian Pacific Railway Limited (CP): Free Inventory Analysis Report
Raytheon Technologies Corporation (RTX): Free Inventory Analysis Report
To read this article on Zacks.com, click here.
Zacks Investment Research
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.